These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 22704996)

  • 1. Determinants of treatment satisfaction of schizophrenia patients: results from the ESPASS study.
    Nordon C; Rouillon F; Barry C; Gasquet I; Falissard B
    Schizophr Res; 2012 Aug; 139(1-3):211-7. PubMed ID: 22704996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evolution of the social autonomy scale (EAS) in schizophrenic patients depending on their management].
    Leguay D; Rouillon F; Azorin JM; Gasquet I; Loze JY; Arnaud R; Dillenschneider A
    Encephale; 2010 Oct; 36(5):397-407. PubMed ID: 21035630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].
    Bret P; Bonnet F; Bret MC; Jaffré A
    Encephale; 2002; 28(4):329-42. PubMed ID: 12232542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia].
    Brunot A; Lachaux B; Sontag H; Casadebaig F; Philippe A; Rouillon F; Cléry-Melin P; Hergueta T; Llorca PM; Moreaudefarges T; Guillon P; Lebrun T
    Encephale; 2002; 28(2):129-38. PubMed ID: 11972139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia.
    Edlinger M; Hofer A; Rettenbacher MA; Baumgartner S; Widschwendter CG; Kemmler G; Neco NA; Fleischhacker WW
    Schizophr Res; 2009 Sep; 113(2-3):246-51. PubMed ID: 19595578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
    Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
    Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.
    Lewis SW; Barnes TR; Davies L; Murray RM; Dunn G; Hayhurst KP; Markwick A; Lloyd H; Jones PB
    Schizophr Bull; 2006 Oct; 32(4):715-23. PubMed ID: 16540702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
    Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
    Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?
    Schmauss M; Diekamp B; Gerwe M; Schreiner A; Ibach B
    Pharmacopsychiatry; 2010 Mar; 43(2):73-80. PubMed ID: 20131207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [RÉALITÉ LT, a pharmacoepidemiological study of semiology and therapeutic strategy of patients with schizophrenia treated by antipsychotic loxapine in routine clinical practice].
    Cousin FR; Samuelian JC; Saoud M; Schmitt L; Vacheron MN; Vidailhet P; Augendre J; Walter M; Tonelli I; Pascal JC
    Encephale; 2012 Feb; 38(1):64-74. PubMed ID: 22381726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia.
    Hatta K; Sato K; Hamakawa H; Takebayashi H; Kimura N; Ochi S; Sudo Y; Asukai N; Nakamura H; Usui C; Kawabata T; Hirata T; Sawa Y
    Schizophr Res; 2009 Aug; 113(1):49-55. PubMed ID: 19553086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients.
    Vernon MK; Revicki DA; Awad AG; Dirani R; Panish J; Canuso CM; Grinspan A; Mannix S; Kalali AH
    Schizophr Res; 2010 May; 118(1-3):271-8. PubMed ID: 20172695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of clozapine on perceptual abnormalities and sensory gating: a preliminary cross-sectional study in schizophrenia.
    Micoulaud-Franchi JA; Aramaki M; Geoffroy PA; Richieri R; Cermolacce M; Faget C; Ystad S; Kronland-Martinet R; Lancon C; Vion-Dury J
    J Clin Psychopharmacol; 2015 Apr; 35(2):184-7. PubMed ID: 25587694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
    Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B
    Am J Psychiatry; 2001 Apr; 158(4):518-26. PubMed ID: 11282684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study.
    Fervaha G; Agid O; Takeuchi H; Foussias G; Remington G
    Schizophr Res; 2013 Dec; 151(1-3):203-8. PubMed ID: 24183751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.